Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDS01ADC and M7824 in Advanced Kaposi Sarcoma
NCT04303117Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Dec 2028
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of NHS-IL-12 in Kaposi sarcoma (KS) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Safety, tolerability and activity. Started Jul 2020; status: recruiting.
02
Drugs
NHS-IL-12
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT04303117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303117.